Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple label-inconsistent statements, including an incorrect dosing frequency (once daily vs labeled twice daily). Several additional claims are not supported by the provided prescribing information.
Category Scores
Accurate Statements
Winlevi is a prescription topical cream.
1 INDICATIONS AND USAGE; 2 DOSAGE AND ADMINISTRATION (topical use only)
Winlevi contains clascoterone 1%.
3 DOSAGE FORM AND STRENGTHS (Cream 1% / 10 mg clascoterone per gram)
Winlevi is used to treat acne vulgaris.
1 INDICATIONS AND USAGE (topical treatment of acne vulgaris)
Winlevi is used in patients 12 years and older.
1 INDICATIONS AND USAGE (patients 12 years of age and older)
Clascoterone is an androgen receptor inhibitor in the skin.
12 CLINICAL PHARMACOLOGY (12.1) (clascoterone is an androgen receptor inhibitor)
Winlevi is applied as a thin layer to acne-prone areas.
2 DOSAGE AND ADMINISTRATION (apply a thin uniform layer ... to the affected area)
Topical androgen-receptor inhibitors can cause local skin reactions.
5 WARNINGS AND PRECAUTIONS (5.1 Local Skin Reactions) (may induce local irritation: erythema/redness, pruritus, scaling/dryness)
Unsupported Statements
Androgens can contribute to acne by increasing oil production and inflammation.
Mechanistic explanation is not stated in the provided label text (12.1 states mechanism of action is unknown and only that it is an androgen receptor inhibitor).
Blocking the androgen receptor helps reduce acne-related effects.
The label states clascoterone is an androgen receptor inhibitor, but the mechanism of action of WINLEVI for acne vulgaris is listed as unknown; the specific benefit statement is not supported.
The dosing frequency of Winlevi is adjusted based on how the skin responds and the prescriber’s instructions.
Label provides a specific regimen (twice per day) and does not describe dose-frequency adjustment based on skin response.
Commonly reported side effects with similar topical acne therapies include skin irritation.
The label provides local skin reactions for WINLEVI, but does not include or support 'commonly reported side effects with similar topical acne therapies' wording.
Commonly reported side effects with similar topical acne therapies include dryness.
Label describes scaling/dryness as local reactions for WINLEVI, but the claim frames them as 'similar topical acne therapies' and is not supported as stated.
Commonly reported side effects with similar topical acne therapies include redness.
Label describes erythema/redness as local reactions for WINLEVI, but does not support 'similar topical acne therapies' framing.
Worsening irritation or signs of an allergic reaction require contacting a clinician.
The provided label text does not include guidance about allergic reactions or instructing to contact a clinician for worsening irritation.
Whether a generic is available for Winlevi depends on the drug’s patent and exclusivity timeline and whether an FDA-approved product has launched.
No section in the provided label text addresses generic availability or patent/exclusivity considerations.
Contradictions
High
AI Statement
Winlevi is usually started once daily.
Label Reference
2 DOSAGE AND ADMINISTRATION (apply a thin uniform layer ... twice per day, in the morning and the evening)
Important Omissions
Labeled administration details: twice-daily (morning and evening) regimen; avoid ophthalmic/oral/vaginal use; avoid application to cuts/abrasions/eczema/sunburned skin; rinse if contact with mucous membranes occurs.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The dosing-frequency contradiction (once daily vs labeled twice daily) is a material alignment issue; additional unsupported generalizations about side effects and contact guidance may mislead, though the label does support that local skin reactions may occur.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Incorrect dosing frequency (once daily) contradicts labeled twice-daily application.
Suggested Improvement
Replace the dosing-frequency claim with the labeled regimen (thin uniform layer twice per day, morning and evening) and remove or rephrase statements not supported by the provided label text (e.g., androgen oil/inflammation mechanism details, dose-frequency adjustment rationale, 'similar therapies' side effect framing, and generic-availability speculation).